Positive Dupixent Phase III results in dermatitis in adolescents

A pivotal Phase III trial evaluating Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (aged 12-17) met its primary and key secondary endpoints.

Dupixent is the first and only biologic to show positive results in this patient population, said French pharma major Sanofi (Euronext: SAN), which has rights to the drug from US biotech Regeneron (Nasdaq: REGN).

"Moderate-to-severe atopic dermatitis can place a particularly significant burden on adolescents, who have to deal with oozing skin lesions with unrelenting, intense itching during their formative years," said George Yancopoulos, president and chief scientific officer of Regeneron. "Dupixent blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation. We are committed to investigating the potential for Dupixent across Type 2 inflammatory diseases with high unmet need including atopic dermatitis, asthma, eosinophilic esophagitis, nasal polyps, chronic obstructive pulmonary disease, and food allergy," he added.